Novartis in flu vaccine pact with SGVI
SVGI is a new company formed by Synthetic Genomics and the not-for-profit research institute, the J Craig Venter Institute (JCVI). As per the pact, Novartis and SGVI will
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Cambia, a new water-soluble, buffered diclofenac potassium powder, is a prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. The companies claimed that Cambia which